Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eszopiclone
Drug ID BADD_D00837
Description Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity[A179827], offering a safer alternative to other drugs used for insomnia. One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia. This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004.[L6769]
Indications and Usage For the treatment of insomnia
Marketing Status Prescription; Discontinued
ATC Code N05CF04
DrugBank ID DB00402
KEGG ID D02624
MeSH ID D000069582
PubChem ID 969472
TTD Drug ID D06ZII
NDC Product Code 63402-191; 80425-0063; 0378-5270; 80425-0098; 65862-969; 43063-795; 63629-5319; 63187-970; 71335-0574; 68462-383; 71205-633; 68462-382; 68788-8077; 65862-968; 76420-024; 68180-322; 63278-1059; 80425-0115; 68180-324; 33342-300; 68788-6953; 33342-301; 61919-587; 70518-1310; 71205-581; 45865-830; 68180-323; 45865-829; 80425-0064; 71335-2002; 68788-7029; 55111-878; 50436-3384; 66022-0106; 71335-0089; 68788-7667; 63187-579; 50090-5084; 63187-843; 43353-185; 63187-817; 55111-619; 71335-0148; 80425-0066; 68462-384; 50090-3553; 0378-5272; 50090-3514; 60429-634; 50436-3383; 55700-581; 68071-2403; 61919-395; 61919-500; 66039-847; 0093-5539; 55700-610; 71335-0116; 61919-462; 60760-325; 55111-617; 71335-0005; 63187-665; 60429-633; 72789-067; 71335-0598; 68071-3376; 47335-587; 61919-119; 0378-5271; 66639-019; 45865-828; 71610-409; 55700-621; 47335-588; 72761-013; 70518-2979; 68788-7169; 63402-190; 47335-586; 43353-200; 72189-099; 65862-967; 50090-4202; 42043-320; 63402-193; 33342-299; 71335-1662; 61919-033; 80425-0062; 71205-384; 55289-014; 61919-514; 42043-321; 63285-831; 43353-097; 60760-511; 63285-832; 71335-1794; 76420-026; 71335-0512; 60760-526; 0093-5537; 11722-057; 71205-236; 76420-027; 80425-0168; 42043-322; 43353-101; 70518-3395; 0093-5538; 80425-0067; 50090-3989; 70518-0815; 80425-0065; 61919-991; 71205-513; 60429-632; 63285-830; 64330-044; 55111-629
Synonyms Eszopiclone | Lunesta | Estorra
Chemical Information
Molecular Formula C17H17ClN6O3
CAS Registry Number 138729-47-2
SMILES CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Suicide attempt19.12.01.0040.006055%
Swelling08.01.03.0150.001514%Not Available
Tension19.06.02.005--Not Available
Thinking abnormal19.10.03.001; 17.02.05.0230.001009%Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tremor17.01.06.0020.001514%
Urethritis20.07.02.001; 11.01.14.008--
Urinary incontinence17.05.01.008; 20.02.02.010--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Uterine haemorrhage24.07.03.004; 21.07.01.005--
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection11.01.10.002; 21.14.02.002--
Vaginal inflammation21.14.02.001--
Vertigo17.02.12.002; 04.04.01.003--
Vestibular disorder17.02.02.008; 04.04.02.001--
Viral infection11.05.04.001--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count increased13.01.06.0130.001009%Not Available
Deep vein thrombosis24.01.02.0030.001009%Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages